RxDoctor Payments Data

Chandrasekhar Vasamreddy, MD

Clinical Cardiac Electrophysiology · Joplin, MONPI 1265572481

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Medical Device Business Services, Inc. at 59.5% of the total. Reporting peaked in 2023 at $10,803 and has fallen 93.5% since, to $701 in 2025.

$25,834in general payments, 2019–2025

Across 308 payments — averaging $83.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$15K
  • Medtronic$3K
  • Biosense Webster, Inc.$2K
  • Abbott$1K
  • Boston Scientific$860
  • Johnson & Johnson$754
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$15,37560%
  • Travel & lodging$1,0124%
  • Food & beverage$8,92735%
  • Education$5202%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,834 in reported general payments places this provider in the 65th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

See all clinical cardiac electrophysiology providers in Missouri

Medicare billing

Part B allowed, 2024
$132,727
Medicare patients
553
Services billed
1,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban725$704,161
XareltoRivaroxaban145$139,414
EntrestoSacubitril/Valsartan37$41,637
MultaqDronedarone Hcl21$19,384
Dofetilide70$11,882
Flecainide Acetate210$8,927
Metoprolol Succinate491$7,337
SotalolSotalol Hcl131$3,369
Amiodarone Hcl181$3,263
Diltiazem 12hr ErDiltiazem Hcl29$2,799
Diltiazem 24hr Er (Cd)Diltiazem Hcl90$2,310
Dabigatran EtexilateDabigatran Etexilate Mesylate12$2,279
Carvedilol254$1,977
Potassium Chloride108$1,684
Atorvastatin Calcium111$1,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$704,161725 claims
Johnson & JohnsonXarelto$754$139,414145 claims
NovartisEntresto$181$41,63737 claims
Sanofi-aventis U.S. LLCMultaq$252$19,38421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 74 clinical cardiac electrophysiology providers in Missouri.

Other clinical cardiac electrophysiology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →